Last €20.02 EUR
Change Today +0.177 / 0.89%
Volume 7.5K
EUZ On Other Exchanges
As of 3:35 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

eckert & ziegler strahlen un (EUZ) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/6/14 - €27.39
52 Week Low
01/6/15 - €16.70
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ECKERT & ZIEGLER STRAHLEN UN (EUZ)

Related News

No related news articles were found.

eckert & ziegler strahlen un (EUZ) Related Businessweek News

No Related Businessweek News Found

eckert & ziegler strahlen un (EUZ) Details

Eckert & Ziegler Strahlen & Medizintechnik AG and its subsidiaries provide isotope technology for medical, scientific, and industrial use primarily in Europe. The company’s Radiation Therapy segment produces and distributes medical devices for brachytherapy, a form of radiotherapy that treats cancer by irradiation from a short distance. This segment offers seeds for the treatment of localised prostate cancer; high dose rate (HDR) afterloaders to treat gynaecological cancers and other tumour sites; applicators for intraluminal, interstitial, intracavitary, and intraoperative treatments, as well as surface mould treatments; and support software of HDR planning. The Radiation Therapy segment also provides products for temporary brachytherapy of eye cancers and radiotherapy accessories. This segment’s products and equipment are intended for use by oncologists, radio-therapists, urologists, ophthalmologists, and medical physicists. Its Isotope Products segment provides sealed and unsealed radiation sources for medical imaging, industrial gauging, measurement and analysis, reference, calibration, and environmental monitoring sources and solutions; and bulk radioisotopes for pharmaceutical, therapeutic, and industrial product manufacturers. This segment offers custom and one-off design and manufacturing services. The company’s Radiopharma segment operates in the field of molecular imaging and nuclear medicine supplying various radiopharmaceuticals, radiochemicals, and related equipment for the synthesis and radiochromatography of PET/SPECT tracers and other radioisotopes. This segment offers products in the categories of radiosynthesis technology, radiochromatography, and radionuclides. Its Environmental Services segment collects, measures, sorts, treats, and packs low level radioactive waste from hospitals, research institutes, and industry for its final disposal. Eckert & Ziegler Strahlen & Medizintechnik AG was founded in 1992 and is headquartered in Berlin, Germany.

716 Employees
Last Reported Date: 11/6/14
Founded in 1992

eckert & ziegler strahlen un (EUZ) Top Compensated Officers

Chairman of The Executive Board, Chief Execut...
Total Annual Compensation: €512.0K
Head of Radiopharma Segment, Member of The Ex...
Total Annual Compensation: €292.0K
Head of Radiation Therapy Segment, Member of ...
Total Annual Compensation: €282.0K
Compensation as of Fiscal Year 2013.

eckert & ziegler strahlen un (EUZ) Key Developments

Eckert & Ziegler Strahlen & Medizintechnik AG Revises Earnings Guidance for the Year 2014

Eckert & Ziegler Strahlen and Medizintechnik AG announced that it expects a 30%-drop in its full-year earnings per share to around EUR 1.25 due to a weak fourth-quarter performance of its radiation therapy unit. In November the company still expected earnings per share of EUR 2 and a net profit of EUR 10.5 million in the full 2014.

Eckert & Ziegler Strahlen & Medizintechnik AG Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Eckert & Ziegler Strahlen & Medizintechnik AG reported unaudited earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, For the quarter, the company reported revenues of EUR 30,628,000 compared to EUR 30,822,000 a year ago. Profit from operations was EUR 3,209,000 compared to EUR 4,641,000 a year ago. EBIT was EUR 3,763,000 compared to EUR 4,540,000 a year ago. Profit before tax was EUR 3,487,000 compared to EUR 4,123,000 a year ago. Profit attributable to the shareholders of the company was EUR 2,297,000 or EUR 0.43 per basic and diluted share compared to EUR 2,260,000 or EUR 0.43 per basic and diluted share a year ago. For the nine months, the company has increased sales by 7% year on year to EUR 92.6 million. Adjusted for exchange rates, sales growth amounted to EUR 7.5 million. Of this amount, EUR 6.9 million relates to acquisitions and EUR 0.6 million to organic sales growth. Despite the increase in sales, EBIT fell by EUR 1.5 million to EUR 10.0 million and EPS to 1.05 EUR in the first nine months of the year. This was mainly attributable to the disappointing development in the Radiation Therapy segment. Although the segment could increase sales by EUR 0.6 million to EUR 19.5 million due to acquired products, the increase remained behind expectations and sales with existing products decreased. Poor sales directly impacted segment profits. EBT EUR 8.9 million compared to EUR 10.6 million a year ago. Profit was EUR 5.6 million or 1.05 per basic and diluted share compared to EUR 6.2 million or 1.18 per basic and diluted Share a year ago. Operating cash flow was EUR 4.9 million compared to EUR 7.0 million a year ago. Purchase of non-current assets was EUR 8,019,000 compared to EUR 6,041,000 a year ago.

Eckert & Ziegler Strahlen & Medizintechnik AG, Q3 2014 Earnings Call, Nov 06, 2014

Eckert & Ziegler Strahlen & Medizintechnik AG, Q3 2014 Earnings Call, Nov 06, 2014


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EUZ:GR €20.02 EUR +0.177

EUZ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
General Electric Co $25.99 USD +0.10
View Industry Companies

Industry Analysis


Industry Average

Valuation EUZ Industry Range
Price/Earnings 11.1x
Price/Sales 0.8x
Price/Book 1.1x
Price/Cash Flow 11.1x
TEV/Sales 0.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ECKERT & ZIEGLER STRAHLEN UN, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at